NanoFUSE is the world’s first bioactive glass with DBM. The current NanoFUSE putty is just one of the six possible variations of this one-of-a-kind synthetic, DBM plus bioactive glass, biologic.
MALDEN, Mass. (PRWEB) March 08, 2019
NanoFUSE Biologics announced today that it will be unveiling new products in development, some that are almost ready for market, at the upcoming American Association of Orthopaedic Surgeons (AAOS) annual meeting in Las Vegas on March 12-16.
NanoFUSE is working with key opinion leaders like Harvard-trained Orthopaedic Spine Surgeon, Dr. Jeffrey Carlson, on varying the handling characteristics of the NanoFUSE putty form. NanoFUSE President, Jake Lubinski, sees opportunities to develop customized forms of this innovative biologic for key surgeons which will further expand the product offering.
After visiting NanoFUSE’s manufacturing site last week, Mr. Lubinski said, “I’m so excited about the engineers and development that’s going on with NanoFUSE right now. Our new offerings are going to be of a caliber to blow you away at AAOS.”
NanoFUSE and KICVentures CEO, Dr. Kingsley R. Chin, said that the launch of new products is important because, “NanoFUSE is the world’s first bioactive glass with DBM. The current NanoFUSE putty is just one of the six possible variations of this one-of-a-kind synthetic, DBM plus bioactive glass, biologic.”
The company will be represented at AAOS at Booth # 2273 from 9:00 am- 5:00 pm and will host a special event with Dr. Patrick Joyner speaking on “NanoFUSE Biologics -My Experience & Early Clinical Results” on Thursday, March 14 from 5:30-6:00 pm at the Venetian Resort Hotel Casino.